Certara, Inc. (CERT)

Swiss National Bank Reduces Stock Holdings in Certara, Inc. (NASDAQ:CERT)

Swiss National Bank cut its position in shares of Certara, Inc. (NASDAQ:CERT – Free Report) by 16.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 220,400 shares of the company’s stock after selling 43,200 shares during the period. Swiss National Bank owned approximately 0.14% of Certara worth $3,877,000 at the end of the most recent quarter. Several other institutional investors and hedge funds also recently bought and sold shares of the company. Commonwealth Equity Services LLC lifted its holdings in Certara by 31.2% in the third quarter. Commonwealth Equity Services LLC now owns 19,055 shares of the company’s stock valued at $277,000 after acquiring an additional 4,528 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Certara by 16.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,117 shares of the company’s stock valued at $351,000 after purchasing an additional 3,482 shares during the last quarter. M&T Bank Corp lifted its stake in shares of Certara by 19.2% in the 3rd quarter. M&T Bank Corp now owns 141,368 shares of the company’s stock valued at $2,055,000 after purchasing an additional 22,759 shares during the last quarter. EFG Asset Management North America Corp. purchased a new position in shares of Certara during the 3rd quarter worth $1,570,000. Finally, Illinois Municipal Retirement Fund acquired a new stake in shares of Certara during the 3rd quarter worth about $941,000. 73.96% of the stock is currently owned by institutional investors and hedge funds. Insider Buying and Selling at Certara In other news, SVP Richard M. Traynor sold 3,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $18.00, for a total value of $54,000.00. Following the completion of the transaction, the senior vice president now owns 173,524 shares in the company, valued at approximately $3,123,432. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, SVP Richard M. Traynor sold 3,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $18.00, for a total value of $54,000.00. Following the completion of the sale, the senior vice president now directly owns 173,524 shares of the company’s stock, valued at $3,123,432. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Patrick F. Smith sold 14,427 shares of the firm’s stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $16.85, for a total value of $243,094.95. Following the transaction, the insider now directly owns 50,091 shares in the company, valued at approximately $844,033.35. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by insiders. Certara Price Performance Shares of CERT opened at $16.08 on Monday. The firm has a market capitalization of $2.59 billion, a price-to-earnings ratio of -41.23, a PEG ratio of 1.61 and a beta of 1.61. The firm’s fifty day simple moving average is $17.41 and its 200-day simple moving average is $16.66. Certara, Inc. has a twelve month low of $11.81 and a twelve month high of $22.65. The company has a current ratio of 3.26, a quick ratio of 3.26 and a debt-to-equity ratio of 0.27. Certara (NASDAQ:CERT – Get Free Report) last announced its quarterly earnings results on Thursday, February 29th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.04). Certara had a positive return on equity of 4.08% and a negative net margin of 17.02%. The business had revenue of $88.01 million for the quarter, compared to analysts’ expectations of $86.80 million. Equities analysts forecast that Certara, Inc. will post 0.29 EPS for the current fiscal year. Analyst Ratings Changes Several research analysts have weighed in on the stock. Barclays increased their target price on shares of Certara from $16.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Thursday, January 25th. UBS Group lifted their target price on shares of Certara from $17.00 to $20.00 and gave the company a “neutral” rating in a report on Friday, March 1st. Leerink Partnrs restated a “market perform” rating on shares of Certara in a research note on Monday, February 26th. Jefferies Financial Group lifted their price objective on Certara from $14.00 to $15.50 and gave the company a “hold” rating in a research note on Friday, March 1st. Finally, SVB Leerink started coverage on Certara in a research note on Monday, February 26th. They set a “market perform” rating and a $19.00 target price on the stock. Seven equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Certara currently has a consensus rating of “Hold” and an average price target of $20.06. View Our Latest Research Report on CERT Certara Company Profile (Free Report) Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.